WO2013157983A1 - Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов - Google Patents
Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов Download PDFInfo
- Publication number
- WO2013157983A1 WO2013157983A1 PCT/RU2012/000688 RU2012000688W WO2013157983A1 WO 2013157983 A1 WO2013157983 A1 WO 2013157983A1 RU 2012000688 W RU2012000688 W RU 2012000688W WO 2013157983 A1 WO2013157983 A1 WO 2013157983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osteoporosis
- bones
- effectiveness
- defining
- cavity formations
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 22
- 238000005755 formation reaction Methods 0.000 title claims abstract description 22
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 35
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 9
- 239000011707 mineral Substances 0.000 claims abstract description 9
- 238000010521 absorption reaction Methods 0.000 claims abstract description 6
- 239000012153 distilled water Substances 0.000 claims abstract description 5
- 230000005855 radiation Effects 0.000 claims abstract description 5
- 238000002601 radiography Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000003745 diagnosis Methods 0.000 claims description 13
- 238000011160 research Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000011835 investigation Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 208000029725 Metabolic bone disease Diseases 0.000 description 9
- 206010049088 Osteopenia Diseases 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940070021 anabolic steroids Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 229960005084 calcitriol Drugs 0.000 description 2
- 235000020964 calcitriol Nutrition 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- YUSCRGFYKCAQHE-HQFNMCNFSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YUSCRGFYKCAQHE-HQFNMCNFSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- ULFUTCYGWMQVIO-PCVRPHSVSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentano Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 ULFUTCYGWMQVIO-PCVRPHSVSA-N 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940090848 divigel Drugs 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 125000001153 fluoro group Chemical class F* 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229960000464 oxandrolone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 1
- 229960001023 tibolone Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
- A61B5/4504—Bones
- A61B5/4509—Bone density determination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/505—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/02—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material
- G01N23/06—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material and measuring the absorption
- G01N23/083—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material and measuring the absorption the radiation being X-rays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N9/00—Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity
- G01N9/24—Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity by observing the transmission of wave or particle radiation through the material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N9/00—Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity
- G01N9/36—Analysing materials by measuring the density or specific gravity, e.g. determining quantity of moisture
Definitions
- a method for the diagnosis of osteoporosis by the method of determining the dynamics of the closure of cavity formations to assess the effectiveness
- the invention relates to medicine, for the diagnosis of osteoporosis and determine the effectiveness of ongoing treatment and preventive effects on conditions associated with osteoporosis.
- Osteoporosis (hereinafter OP) is a metabolic disease of the skeleton, characterized by a decrease in bone mass per unit volume and a violation of the microarchitectonics of bone tissue, with the formation of porous formations in the bones, leading to a decrease in the amount of calcium in the bones and a high risk of fractures of any bones, including the femoral neck.
- estrogen hormones (Devina, divigel, divitren, estrofem, clemen, climonorm, tibolone, etc.),
- fluorine derivatives sodium fluoride, monoflurophosphate
- Standard radiography is one of the required research methods. It allows morphometric analysis of vertebral bodies, reveals the characteristic deformations of the vertebral bodies, and with high accuracy to establish fractures of the vertebral bodies.
- a standard radiograph is the main and most affordable method for diagnosing osteoporosis. However, this diagnostic method is late. Since it allows to detect osteoporosis only with bone loss of more than 30-40%. Therefore, radiography is unacceptable for the early quantitative diagnosis of osteopenia, osteoporosis, and therapy control.
- BMD bone mineral density
- Osteometr has developed a series of instruments for assessing BMD in the distal forearm.
- DTX-100, DTX-200 devices have special software for calculating the annual loss of bone tissue and allow predicting the risk of bone fractures.
- Modern osteometers allow you to measure BMD in various parts of the body, including the neck of the thigh and vertebral bodies. All osteometers work in two scales.
- T-scale means the number of standard deviations above or below the average peak bone mass. The T-criterion decreases in parallel with a gradual decrease in bone mass with increasing age and is used to evaluate BMD in adults.
- ⁇ - the scale means the number of standard deviations above or below the average for people of the same age.
- BMD is defined in absolute units, standard deviations between the BMD of the patient and the age norm of healthy children and adolescents of the same age and gender.
- IPC norm - T-test readings from +1 to -1 standard deviations (SD) from peak bone mass.
- Osteoporosis of the II degree - BMD from - 2.5 or less in the presence of osteoporotic bone fractures.
- This method takes into account only the quantitative characteristic of bone mineralization, which, depending on the patient’s body weight, region, gender, skin color, can significantly differ from standard values. For example, women with low body weight, as a rule, have lower BMD values than women with high weight, especially with obesity, which complicates the quantitative characterization of changes in osteoporosis. In this case, an objective qualitative assessment of the effectiveness of the drug in the treatment of osteoporosis on the basis of an increase or decrease in BMD cannot be done. This is facilitated by the lack of regional databases on regional regulations of the IPC.
- the objective of the claimed invention is to objectively evaluate the effectiveness of the drug (s) (osteoprotector) and to determine cavity formations in the trabecular parts of the bones. It is proposed to improve the diagnostic capabilities of computer osteometers by determining cavity formations in osteoporosis and to determine the severity of the disease not only by mineral density, but also by the presence of cavities in the trabecular parts of the bones.
- Example 1 Patient A. Decrease in BMD on T-skore from -2.1 to - 2.3. CO. This, according to the WHO classification, fits into the diagnosis of osteopenia of the 3rd degree. However, in this patient, a 2x4 mm cavity is defined in the trabecular part of the ulna. This is the main of 2 indicators - a sign of osteoporosis (Fig. 1).
- Example 2 Patient B.
- BMD bone mineral density
- Fig. 2 osteopenia
- the BMD readings are reduced, for example, to –2.4 SD (osteopenia), however, when detecting cavity formations in the bones, such patients need to be diagnosed with osteoporosis. Especially in cases where in the dynamics of observation these cavities are enlarged or there is a history of bone fractures.
- Example 2 shows the results of therapy after 12 months.
- mineralization increased from -3.4 to -1.9 CO (from osteoporosis to osteopenia of the 2nd degree), and cavity formations increased. Therefore, if we evaluate the effectiveness of treatment on the DTX 200 device according to the IPC, we can evaluate this as a positive result and, therefore, about the effectiveness of this drug (calcium Dz Nycomed ”) and the possibility of discontinuing the drug or reducing its dose, reducing the duration of treatment, etc.
- Example 2 Patient E. Postmenopausal osteoporosis. Abdominal masses in metaphysical (trabecular) areas of bones, BMD on the T scale — 3.4 SD (Fig. 3).
- the aim of this invention is to develop a method for improving the diagnosis of osteoporosis and an objective assessment of the effectiveness of the drug (s) (osteoprotector).
- test group and the comparison group include a homogeneous group of patients by age and gender.
- Patients with IPC from -2.5CO or less Patients only women with primary osteoporosis (for example, postmenopausal). Or only men with primary osteoporosis.
- X-ray absorption osteometry is performed in both groups before treatment and every three to four months.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dentistry (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/395,480 US20150223770A1 (en) | 2012-04-19 | 2012-08-21 | Method for diagnosing osteoporosis by a method for defining the dynamics of closing cavity formations in order to assess the effectiveness of using various osteoprotectors |
CA2870825A CA2870825C (en) | 2012-04-19 | 2012-08-21 | A method for diagnosing osteoporosis using a method for determining the dynamics of closure of cavities to evaluate the effectiveness of using various bone protectors |
BR112014025994-1A BR112014025994B1 (pt) | 2012-04-19 | 2012-08-21 | Método de medição de densidade mineral do tecido ósseo utilizando absorção radiológica |
AU2012377477A AU2012377477A1 (en) | 2012-04-19 | 2012-08-21 | Method for diagnosing osteoporosis by a method for defining the dynamics of closing cavity formations in order to assess the effectiveness of using various osteoprotectors |
EA201401156A EA027158B1 (ru) | 2012-04-19 | 2012-08-21 | Способ диагностики остеопороза и способ определения эффективности препарата для лечения остеопороза |
JP2015506934A JP2015514499A (ja) | 2012-04-19 | 2012-08-21 | 各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断法 |
EP12874860.5A EP2839782A4 (en) | 2012-04-19 | 2012-08-21 | METHOD FOR THE DIAGNOSIS OF OSTEOPOROSIS USING A METHOD OF DETERMINING THE CLOSING DYNAMIC OF CAVITY FORMATIONS FOR EVOLVING THE EFFICIENCY OF USING DIFFERENT OSTEOPROTECTORS |
CN201280074013.2A CN104363832A (zh) | 2012-04-19 | 2012-08-21 | 骨质疏松诊断方法,用于评估不同骨骼促进剂的效果的闭合孔隙结构动态测定法 |
UAA201412407A UA114626C2 (ru) | 2012-04-19 | 2012-08-21 | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
IL235170A IL235170B (en) | 2012-04-19 | 2014-10-19 | A method for diagnosing osteoporosis using a method for determining the dynamics of closing pores in order to determine the effectiveness of the use of different bone protectors |
IN9781DEN2014 IN2014DN09781A (ru) | 2012-04-19 | 2014-11-19 | |
AU2017232044A AU2017232044B2 (en) | 2012-04-19 | 2017-09-19 | Method for diagnosing osteoporosis by a method for defining the dynamics of closing cavity formations in order to assess the effectiveness of using various osteoprotectors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012115655 | 2012-04-19 | ||
RU2012115655/14A RU2511430C2 (ru) | 2012-04-19 | 2012-04-19 | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013157983A1 true WO2013157983A1 (ru) | 2013-10-24 |
Family
ID=49383801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2012/000688 WO2013157983A1 (ru) | 2012-04-19 | 2012-08-21 | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150223770A1 (ru) |
EP (1) | EP2839782A4 (ru) |
JP (3) | JP2015514499A (ru) |
CN (1) | CN104363832A (ru) |
AU (2) | AU2012377477A1 (ru) |
BR (1) | BR112014025994B1 (ru) |
CA (1) | CA2870825C (ru) |
EA (1) | EA027158B1 (ru) |
IL (1) | IL235170B (ru) |
IN (1) | IN2014DN09781A (ru) |
RU (1) | RU2511430C2 (ru) |
UA (1) | UA114626C2 (ru) |
WO (1) | WO2013157983A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104548373A (zh) * | 2015-01-01 | 2015-04-29 | 岳耀升 | 骨质疏松治疗仪 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2511430C2 (ru) * | 2012-04-19 | 2014-04-10 | Общество С Ограниченной Ответственностью "Парафарм" | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
RU2607304C1 (ru) * | 2015-11-23 | 2017-01-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" (НИИ КПССЗ) | Способ прогнозирования годовой антиостеопоротической эффективности менопаузальной гормональной терапии |
CN108538393B (zh) * | 2018-04-02 | 2021-12-10 | 重庆邮电大学 | 基于大数据的骨质质量评估专家系统及预测模型建立方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2159577C1 (ru) * | 2000-04-11 | 2000-11-27 | Михайлов Марс Константинович | Способ определения содержания минерального вещества в костной ткани |
RU2305491C2 (ru) * | 2003-12-05 | 2007-09-10 | Российская медицинская академия последипломного образования Министерства здравоохранения Российской Федерации (РМАПО МЗ РФ) | Способ исследования и диагностики патологии костной ткани при сахарном диабете |
RU2412650C1 (ru) * | 2009-06-01 | 2011-02-27 | Закрытое Акционерное Общество "Рентгенпром" (Зао "Рентгенпром") | Способ определения величин минеральной и объемной плотности костной ткани, относящийся к одноэнергетической рентгеновской денситометрии |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0775606B2 (ja) * | 1993-06-30 | 1995-08-16 | アロカ株式会社 | 生体組織診断装置 |
JP3229179B2 (ja) * | 1995-11-02 | 2001-11-12 | 帝人株式会社 | 骨計測方法 |
JPH09327462A (ja) * | 1996-06-10 | 1997-12-22 | Asuka B F Kk | 骨評価装置用の踵骨部測定体 |
JP3499761B2 (ja) * | 1998-10-22 | 2004-02-23 | 帝人株式会社 | 骨画像処理方法及び骨強度評価方法 |
US6430427B1 (en) * | 1999-02-25 | 2002-08-06 | Electronics And Telecommunications Research Institute | Method for obtaining trabecular index using trabecular pattern and method for estimating bone mineral density using trabecular indices |
US6285901B1 (en) * | 1999-08-25 | 2001-09-04 | Echo Medical Systems, L.L.C. | Quantitative magnetic resonance method and apparatus for bone analysis |
CA2425656A1 (en) * | 2000-10-11 | 2002-04-18 | Philipp Lang | Methods and devices for analysis of x-ray images |
US8639009B2 (en) * | 2000-10-11 | 2014-01-28 | Imatx, Inc. | Methods and devices for evaluating and treating a bone condition based on x-ray image analysis |
US6975894B2 (en) * | 2001-04-12 | 2005-12-13 | Trustees Of The University Of Pennsylvania | Digital topological analysis of trabecular bone MR images and prediction of osteoporosis fractures |
AU2002360478A1 (en) * | 2001-12-05 | 2003-06-17 | The Trustees Of The University Of Pennsylvania | Virtual bone biopsy |
US8085898B2 (en) * | 2009-05-08 | 2011-12-27 | Osteometer Meditech, Inc. | Apparatus for bone density assessment and monitoring |
JP2005034539A (ja) * | 2003-07-18 | 2005-02-10 | Ibaraki Prefecture | 骨密度分布測定機能付きx線画像診断装置 |
US20050015002A1 (en) * | 2003-07-18 | 2005-01-20 | Dixon Gary S. | Integrated protocol for diagnosis, treatment, and prevention of bone mass degradation |
JP2008514368A (ja) * | 2004-09-30 | 2008-05-08 | ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア | 特性判定方法、記録装置、評価方法 |
EP1851237A4 (en) * | 2005-02-16 | 2009-01-07 | Univ California | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS |
JP2008206560A (ja) * | 2007-02-23 | 2008-09-11 | Kyushu Univ | 骨塩量測定装置 |
US8679019B2 (en) * | 2007-12-03 | 2014-03-25 | Bone Index Finland Oy | Method for measuring of thicknesses of materials using an ultrasound technique |
JP5537346B2 (ja) * | 2010-09-06 | 2014-07-02 | 株式会社日立メディコ | 画像診断支援装置、画像診断支援方法 |
RU2511430C2 (ru) * | 2012-04-19 | 2014-04-10 | Общество С Ограниченной Ответственностью "Парафарм" | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
-
2012
- 2012-04-19 RU RU2012115655/14A patent/RU2511430C2/ru active
- 2012-08-21 CN CN201280074013.2A patent/CN104363832A/zh active Pending
- 2012-08-21 EA EA201401156A patent/EA027158B1/ru active IP Right Revival
- 2012-08-21 JP JP2015506934A patent/JP2015514499A/ja active Pending
- 2012-08-21 BR BR112014025994-1A patent/BR112014025994B1/pt active IP Right Grant
- 2012-08-21 CA CA2870825A patent/CA2870825C/en active Active
- 2012-08-21 EP EP12874860.5A patent/EP2839782A4/en not_active Ceased
- 2012-08-21 WO PCT/RU2012/000688 patent/WO2013157983A1/ru active Application Filing
- 2012-08-21 US US14/395,480 patent/US20150223770A1/en active Pending
- 2012-08-21 AU AU2012377477A patent/AU2012377477A1/en not_active Abandoned
- 2012-08-21 UA UAA201412407A patent/UA114626C2/ru unknown
-
2014
- 2014-10-19 IL IL235170A patent/IL235170B/en active IP Right Grant
- 2014-11-19 IN IN9781DEN2014 patent/IN2014DN09781A/en unknown
-
2017
- 2017-09-19 AU AU2017232044A patent/AU2017232044B2/en active Active
- 2017-11-06 JP JP2017213612A patent/JP6543317B2/ja active Active
- 2017-11-06 JP JP2017213611A patent/JP2018030016A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2159577C1 (ru) * | 2000-04-11 | 2000-11-27 | Михайлов Марс Константинович | Способ определения содержания минерального вещества в костной ткани |
RU2305491C2 (ru) * | 2003-12-05 | 2007-09-10 | Российская медицинская академия последипломного образования Министерства здравоохранения Российской Федерации (РМАПО МЗ РФ) | Способ исследования и диагностики патологии костной ткани при сахарном диабете |
RU2412650C1 (ru) * | 2009-06-01 | 2011-02-27 | Закрытое Акционерное Общество "Рентгенпром" (Зао "Рентгенпром") | Способ определения величин минеральной и объемной плотности костной ткани, относящийся к одноэнергетической рентгеновской денситометрии |
Non-Patent Citations (3)
Title |
---|
BARTL S. ET AL.: "Secondary osteoporosis: pathogenesis, types, diagnostics and therapy.", RADIOLOGE, vol. 51, no. 4, April 2011 (2011-04-01), pages 307 - 24, XP055173924 * |
DATABASE PUBMED accession no. 1455799 * |
STRUKOV V.I. ET AL.: "Kliniko-metabolicheskie osobennosti rakhita u detei, rodivshikhsya ot materei s osteopenicheskim sindromom.", PEDIATRIYA, 2004, pages 24 - 25, XP008175307 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104548373A (zh) * | 2015-01-01 | 2015-04-29 | 岳耀升 | 骨质疏松治疗仪 |
CN106924881A (zh) * | 2015-01-01 | 2017-07-07 | 充爱军 | 一种安全实用的骨质疏松治疗仪 |
Also Published As
Publication number | Publication date |
---|---|
JP2018030016A (ja) | 2018-03-01 |
IN2014DN09781A (ru) | 2015-07-31 |
RU2511430C2 (ru) | 2014-04-10 |
US20150223770A1 (en) | 2015-08-13 |
CN104363832A (zh) | 2015-02-18 |
BR112014025994A2 (pt) | 2017-06-27 |
JP6543317B2 (ja) | 2019-07-10 |
AU2012377477A1 (en) | 2014-12-11 |
RU2012115655A (ru) | 2013-10-27 |
EP2839782A1 (en) | 2015-02-25 |
EA027158B1 (ru) | 2017-06-30 |
IL235170B (en) | 2021-06-30 |
AU2017232044B2 (en) | 2019-05-16 |
AU2017232044A1 (en) | 2017-10-12 |
JP2018030017A (ja) | 2018-03-01 |
CA2870825A1 (en) | 2013-10-24 |
JP2015514499A (ja) | 2015-05-21 |
IL235170A0 (en) | 2014-12-31 |
EP2839782A4 (en) | 2016-01-06 |
CA2870825C (en) | 2023-09-26 |
EA201401156A1 (ru) | 2015-05-29 |
UA114626C2 (ru) | 2017-07-10 |
BR112014025994B1 (pt) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Engelke et al. | Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions | |
Krieg et al. | Effects of anti-resorptive agents on trabecular bone score (TBS) in older women | |
AU2017232044B2 (en) | Method for diagnosing osteoporosis by a method for defining the dynamics of closing cavity formations in order to assess the effectiveness of using various osteoprotectors | |
Watanabe et al. | The influence of lumbar muscle volume on curve progression after skeletal maturity in patients with adolescent idiopathic scoliosis: a long-term follow-up study | |
Dambacher et al. | Highly precise peripheral quantitative computed tomography for the evaluation of bone density, loss of bone density and structures: consequences for prophylaxis and treatment | |
Blake et al. | Dual energy x-ray absorptiometry and its clinical applications | |
Crabtree et al. | Bone densitometry: current status and future perspective | |
Leere et al. | Associations between trabecular bone score and biochemistry in surgically vs conservatively treated outpatients with primary hyperparathyroidism: A retrospective cohort study | |
Sturtridge et al. | Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 2. The use of bone density measurement in the diagnosis and management of osteoporosis. | |
Kullenberg | Reference database for dual X-ray and laser Calscan bone densitometer | |
Schmidutz et al. | Cortical bone thickness predicts the quantitative bone mineral density of the proximal humerus | |
Ito et al. | Which bone densitometry and which skeletal site are clinically useful for monitoring bone mass? | |
Sturtridge et al. | The use of bone density measurement in the diagnosis and management of osteoporosis | |
Rolla et al. | Bone densitometry by radiofrequency echographic multi-spectrometry (REMS) in acromegaly patients | |
Glüer | Quantitative computed tomography in children and adults | |
Du et al. | Quantitative ultrasound measurements of bone quality in female adolescents with idiopathic scoliosis compared to normal controls | |
Guglielmi et al. | Three-year prospective study on fracture risk in postmenopausal women by quantitative ultrasound at the phalanges | |
Hawkinson et al. | Technical white paper: bone densitometry | |
Kondo et al. | Bone formation parameters of the biopsied ilium differ between subtrochanteric and diaphyseal atypical femoral fractures in bisphosphonate-treated patients | |
Guler et al. | A comparative overview of metatarsal stress fractures in premenopausal and postmenopausal women: our single-centre experience with eighty-one patients | |
Pisaruk et al. | Method for assessment of the biological age of the musculoskeletal system | |
Guglielmi et al. | Bone densitometry: current status and future trends | |
Lin et al. | N-terminal telopeptides of type I collagen and bone mineral density for early diagnosis of nonunion: An experimental study in rabbits | |
Zaredi et al. | The role of the Radiology Technologist in the assessment of DXA unit precision error and Least Significant Change/LSC. | |
Coria et al. | Densidad mineral ósea volumétrica medida por tomografía de cálculo cuantitativo: valores de referencia para la población pediátrica mexicana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12874860 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2870825 Country of ref document: CA Ref document number: 2015506934 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201412407 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201401156 Country of ref document: EA Ref document number: 2012874860 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014025994 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2012377477 Country of ref document: AU Date of ref document: 20120821 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14395480 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112014025994 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141017 |